Daniel A Antiporta1, Yuri L Cutipé2, Maria Mendoza2, David D Celentano3, Elizabeth A Stuart4, Andrea Bruni5. 1. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. dantiporta@jhu.edu. 2. Mental Health Direction, Ministry of Health, Lima, Peru. 3. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. 4. Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. 5. Pan American Health Organization/World Health Organization, Lima, Peru.
Abstract
BACKGROUND: Population health and well-being in Latin America, the current epicenter of the COVID-19 pandemic, has been severely affected during the past semester. Despite the growing evidence about the link between the pandemic, its control measures, and mental health worldwide, there is still no regional evidence of the potential mental health impact. We describe the prevalence and distribution of depressive symptoms across demographic and socioeconomic risk factors in the Peruvian population amidst a national lockdown during the COVID-19 pandemic. METHODS: Cross-sectional study conducted during the community transmission phase and national lockdown in Peru (May 4th-16th, 2020). We recorded 64,493 responses from adult Peruvian residents through an opt-in online questionnaire. All analyses were weighted using raking based on proportions of sociodemographic variables from the last Peruvian census in 2017. The prevalence of depressive symptoms was calculated using the Patient Health Questionnaire (PHQ-9) score of 10 or more. We identified associated demographic and socioeconomic factors by prior mental health diagnosis. Sensitivity analysis considered an alternative cut-off point for depressive symptoms of PHQ-9 ≥ 14. RESULTS: A total of 57,446 participants were included in the analytical sample. A third of the participants (n = 23,526, unweighted) showed depressive symptoms in the 2 weeks prior to the study. Participants who reported a previous mental health diagnosis doubled the sample prevalence of depressive symptoms (59, 95%CI 56.7, 61.4%) of those without a prior diagnosis. Psychosocial and functioning reactions were largely more prevalent among females and young adults. A dose-response relationship was found between household income and depressive symptoms across previous mental health diagnosis strata, being as low as 32% less in the wealthiest than the most impoverished group (PR: 0.68, 95%CI 0.58,0.79). Other critical factors associated with a higher burden of depressive symptoms were lower education level, single, unemployed, and chronic comorbidity. CONCLUSIONS: An increased burden of depressive symptoms and psychosocial reactions has emerged during the COVID-19 pandemic in Peru compared to previous years. The mental health burden disproportionately affects women, the younger population, and those with low income and education. As the country eases the social distancing measures, it is crucial to use local evidence to adjust public health policies and mental health services to the renewed population needs.
BACKGROUND: Population health and well-being in Latin America, the current epicenter of the COVID-19 pandemic, has been severely affected during the past semester. Despite the growing evidence about the link between the pandemic, its control measures, and mental health worldwide, there is still no regional evidence of the potential mental health impact. We describe the prevalence and distribution of depressive symptoms across demographic and socioeconomic risk factors in the Peruvian population amidst a national lockdown during the COVID-19 pandemic. METHODS: Cross-sectional study conducted during the community transmission phase and national lockdown in Peru (May 4th-16th, 2020). We recorded 64,493 responses from adult Peruvian residents through an opt-in online questionnaire. All analyses were weighted using raking based on proportions of sociodemographic variables from the last Peruvian census in 2017. The prevalence of depressive symptoms was calculated using the Patient Health Questionnaire (PHQ-9) score of 10 or more. We identified associated demographic and socioeconomic factors by prior mental health diagnosis. Sensitivity analysis considered an alternative cut-off point for depressive symptoms of PHQ-9 ≥ 14. RESULTS: A total of 57,446 participants were included in the analytical sample. A third of the participants (n = 23,526, unweighted) showed depressive symptoms in the 2 weeks prior to the study. Participants who reported a previous mental health diagnosis doubled the sample prevalence of depressive symptoms (59, 95%CI 56.7, 61.4%) of those without a prior diagnosis. Psychosocial and functioning reactions were largely more prevalent among females and young adults. A dose-response relationship was found between household income and depressive symptoms across previous mental health diagnosis strata, being as low as 32% less in the wealthiest than the most impoverished group (PR: 0.68, 95%CI 0.58,0.79). Other critical factors associated with a higher burden of depressive symptoms were lower education level, single, unemployed, and chronic comorbidity. CONCLUSIONS: An increased burden of depressive symptoms and psychosocial reactions has emerged during the COVID-19 pandemic in Peru compared to previous years. The mental health burden disproportionately affects women, the younger population, and those with low income and education. As the country eases the social distancing measures, it is crucial to use local evidence to adjust public health policies and mental health services to the renewed population needs.
Authors: María Calderón; Juan Antonio Gálvez-Buccollini; Gloria Cueva; Carlos Ordoñez; Carlos Bromley; Fabián Fiestas Journal: Rev Peru Med Exp Salud Publica Date: 2012 Oct-Dec
Authors: Brooke Levis; Andrea Benedetti; John P A Ioannidis; Ying Sun; Zelalem Negeri; Chen He; Yin Wu; Ankur Krishnan; Parash Mani Bhandari; Dipika Neupane; Mahrukh Imran; Danielle B Rice; Kira E Riehm; Nazanin Saadat; Marleine Azar; Jill Boruff; Pim Cuijpers; Simon Gilbody; Lorie A Kloda; Dean McMillan; Scott B Patten; Ian Shrier; Roy C Ziegelstein; Sultan H Alamri; Dagmar Amtmann; Liat Ayalon; Hamid R Baradaran; Anna Beraldi; Charles N Bernstein; Arvin Bhana; Charles H Bombardier; Gregory Carter; Marcos H Chagas; Dixon Chibanda; Kerrie Clover; Yeates Conwell; Crisanto Diez-Quevedo; Jesse R Fann; Felix H Fischer; Leila Gholizadeh; Lorna J Gibson; Eric P Green; Catherine G Greeno; Brian J Hall; Emily E Haroz; Khalida Ismail; Nathalie Jetté; Mohammad E Khamseh; Yunxin Kwan; Maria Asunción Lara; Shen-Ing Liu; Sonia R Loureiro; Bernd Löwe; Ruth Ann Marrie; Laura Marsh; Anthony McGuire; Kumiko Muramatsu; Laura Navarrete; Flávia L Osório; Inge Petersen; Angelo Picardi; Stephanie L Pugh; Terence J Quinn; Alasdair G Rooney; Eileen H Shinn; Abbey Sidebottom; Lena Spangenberg; Pei Lin Lynnette Tan; Martin Taylor-Rowan; Alyna Turner; Henk C van Weert; Paul A Vöhringer; Lynne I Wagner; Jennifer White; Kirsty Winkley; Brett D Thombs Journal: J Clin Epidemiol Date: 2020-02-24 Impact factor: 7.407
Authors: Dian-Jeng Li; Nai-Ying Ko; Yi-Lung Chen; Peng-Wei Wang; Yu-Ping Chang; Cheng-Fang Yen; Wei-Hsin Lu Journal: Int J Environ Res Public Health Date: 2020-06-22 Impact factor: 3.390
Authors: Ross W Paterson; Rachel L Brown; Laura Benjamin; Ross Nortley; Sarah Wiethoff; Tehmina Bharucha; Dipa L Jayaseelan; Guru Kumar; Rhian E Raftopoulos; Laura Zambreanu; Vinojini Vivekanandam; Anthony Khoo; Ruth Geraldes; Krishna Chinthapalli; Elena Boyd; Hatice Tuzlali; Gary Price; Gerry Christofi; Jasper Morrow; Patricia McNamara; Benjamin McLoughlin; Soon Tjin Lim; Puja R Mehta; Viva Levee; Stephen Keddie; Wisdom Yong; S Anand Trip; Alexander J M Foulkes; Gary Hotton; Thomas D Miller; Alex D Everitt; Christopher Carswell; Nicholas W S Davies; Michael Yoong; David Attwell; Jemeen Sreedharan; Eli Silber; Jonathan M Schott; Arvind Chandratheva; Richard J Perry; Robert Simister; Anna Checkley; Nicky Longley; Simon F Farmer; Francesco Carletti; Catherine Houlihan; Maria Thom; Michael P Lunn; Jennifer Spillane; Robin Howard; Angela Vincent; David J Werring; Chandrashekar Hoskote; Hans Rolf Jäger; Hadi Manji; Michael S Zandi Journal: Brain Date: 2020-10-01 Impact factor: 13.501
Authors: Jeff Huarcaya-Victoria; Beltran Villarreal-Rao; Matilde Luna; Wendoline Rojas-Mendoza; Christoper A Alarcon-Ruiz; David Villarreal-Zegarra; Ana L Vilela-Estrada; Samantha Ramírez Journal: Int J Environ Res Public Health Date: 2022-04-28 Impact factor: 4.614
Authors: Claudia Elera-Fitzcarrald; Jeff Huarcaya-Victoria; Graciela S Alarcón; Manuel F Ugarte-Gil Journal: Clin Rheumatol Date: 2021-05-28 Impact factor: 3.650
Authors: Amy Tausch; Renato Oliveira E Souza; Carmen Martinez Viciana; Claudina Cayetano; Jarbas Barbosa; Anselm Jm Hennis Journal: Lancet Reg Health Am Date: 2021-11-15
Authors: David Villarreal-Zegarra; Rubí Paredes-Angeles; Nikol Mayo-Puchoc; Ana L Vilela-Estada; Anthony Copez-Lonzoy; Jeff Huarcaya-Victoria Journal: BMC Psychiatry Date: 2022-10-10 Impact factor: 4.144
Authors: Stephen X Zhang; Hao Huang; Jizhen Li; Mayra Antonelli-Ponti; Scheila Farias de Paiva; José Aparecido da Silva Journal: Int J Environ Res Public Health Date: 2021-06-30 Impact factor: 3.390